AstraZeneca-Daiichi Sankyo's Datopotamab deruxtecan improves survival in advanced lung cancer, TROPION-Lung01 Phase III trial shows.
AstraZeneca and Daiichi Sankyo's Datopotamab deruxtecan (Dato-DXd) shows promise in improving survival rates for advanced lung cancer patients with nonsquamous non-small cell lung cancer (NSCLC), as per TROPION-Lung01 Phase III trial results. It has demonstrated a clinically meaningful overall survival (OS) improvement compared to standard-of-care chemotherapy, docetaxel, with a favorable safety profile.
May 27, 2024
4 Articles